Peginterferon alfa-2b biosimilar - Harvest Moon Pharmaceuticals
Alternative Names: PEG alpha interferon 2b biosimilar - Harvest MoonLatest Information Update: 12 Jan 2022
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Antihaemorrhagics; Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
- Mechanism of Action Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C; Multiple myeloma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (SC, Injection)
- 11 Oct 2013 Peginterferon alfa-2b biosimilar is available for licensing as of 11 Oct 2013. http://harvestmoonpharma.com